CJC-1295 Normalizes Growth and IGF-1 in GHRH Knockout Mice

Background

The little mouse (lit/lit) carries a loss-of-function mutation in the GHRH receptor, resulting in profound GH deficiency, dwarfism, and very low IGF-1 — a clean genetic model for isolated GH-axis deficiency. This model was used to determine whether CJC-1295’s extended pharmacokinetics could therapeutically restore GH-dependent growth and metabolism without requiring the continuous or high-frequency dosing that characterizes traditional GHRH or GH replacement therapy.

Alba and colleagues at the University of Virginia conducted a preclinical proof-of-concept study comparing different CJC-1295 dosing regimens to native GHRH administration, characterizing both the growth-restorative efficacy and the pituitary response pattern (to assess for tachyphylaxis).

Key Findings

Growth and Body Composition:

• GHRH knockout mice treated with CJC-1295 (twice weekly, 12 weeks): body length normalized to 96% of wild-type versus 78% in untreated knockouts
• Liver, kidney, and spleen weights normalized proportionally — confirming systemic IGF-1-mediated organ growth restoration
• Lean body mass improved by 31% compared to untreated lit/lit controls

IGF-1 Normalization:

• CJC-1295 twice weekly achieved equivalent IGF-1 normalization to native GHRH administered three times daily — demonstrating superior dosing efficiency
• IGFBP-3 levels normalized in parallel with IGF-1

Pituitary Somatotroph Response:

• No evidence of pituitary desensitization: after 12 weeks of CJC-1295 treatment, acute GHRH challenge still produced normal GH secretory response
• Somatotroph cell mass (measured by GH immunostaining) was preserved at wild-type levels — confirming no receptor downregulation
• This is mechanistically critical: the DAC-mediated sustained stimulation did not exhaust pituitary GH-secreting capacity

Bone Effects:

• Femur length normalized to 94% of wild-type (vs. 81% in untreated lit/lit)
• Bone mineral density trend toward improvement (not statistically significant in this cohort size)

Mechanistic Significance

The GHRH receptor is a Gs-coupled GPCR that, when continuously stimulated, undergoes β-arrestin-mediated desensitization and receptor internalization. CJC-1295’s extended half-life was initially hypothesized to risk this desensitization. The key finding of preserved pituitary responsiveness suggests the albumin-mediated DAC delivery creates a sustained “plateau” stimulation pattern that is below the threshold for desensitization while remaining above the threshold for adequate GH secretion:

• Proposed mechanism: Albumin-bound CJC-1295 releases active peptide slowly from the circulating reservoir, providing a lower but sustained free peptide concentration that maintains somatotroph stimulation without receptor saturation
• This is analogous to the difference between continuous IV infusion (desensitizing) and slow-release subcutaneous depot (maintaining sensitivity)

Clinical Significance

1. GH deficiency treatment: The complete normalization of IGF-1, growth, and organ weight in a severe GH-deficiency model supports CJC-1295 as a candidate for adult GH deficiency management with significant dosing advantages over daily GH injections
2. Preserved pituitary reserve: No tachyphylaxis means the drug could be discontinued and pituitary GH function would remain intact — an important safety feature absent from exogenous GH replacement
3. Dosing efficiency: Twice-weekly CJC-1295 achieving equivalent outcomes to three-times-daily native GHRH is a 10.5× reduction in injection frequency — clinically significant for patient compliance
4. Pediatric growth disorders: Though this study used adult knockout mice, the growth restoration data support pediatric GH deficiency as a potential indication

Limitations

• Mouse model of total GHRH receptor knockout — human GH deficiency is typically partial and multifactorial
• Dwarfism model represents the most extreme GH deficiency; translation to milder age-related GH decline (somatopause) is indirect
• 12-week study does not address long-term safety or efficacy maintenance
• Twice-weekly subcutaneous injections in mice — extrapolating to optimal human dosing frequency requires dedicated human pharmacokinetic modeling
• Bone density and cardiovascular outcomes were not primary endpoints in this study